- The “proposal” by Royalty Pharma remains an indication of interest, is highly conditional and may or may not lead to an offer being made for the entire issued share capital of the Company.
- The highly conditional indication of interest is opportunistic in its timing.
- Any credible proposal which may be made by Royalty Pharma or any other party will of course be considered by the Company alongside the strategic transactions and unique investment thesis referred to in our recent announcements in February 2013.
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's statement by Royalty Management, LLC (Royalty Pharma). Elan’s position remains as outlined on February 25, 2013: